Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. SK3 Group Inc. (SKTO) Message Board

"Medical Marijuana: 76% Of Doctors Would Prescribe

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 36729
Posted On: 12/13/2013 4:44:22 PM
Posted By: bellsandwhistles
"Medical Marijuana: 76% Of Doctors Would Prescribe It, Poll Finds"

"Three out of four doctors would prescribe marijuana to a patient who was experiencing pain from cancer, according to the results of a poll published in the New England Journal of Medicine."

Very pleased both low and high dose Dharmanol™ are ready for California distribution to collectives and dispensaries. There was a thought that just low dose would go first, but this news is much more than doubly good. There are very important media looking at this story. The high dose Dharmanol™ for cancer is the dramatic play. 

PR
"Dharmanol™ (pronounced DAR-mah-nol) will be available in two forms: low-dose, non-psychoactive tablets and high-doses directed to cancer."

"At the opposite end of the spectrum is using Dharmanol™ for cancer. Very large doses can be taken daily with no psychoactive effects. On observing the spectacular results that patients are receiving with standard Simpson therapy, most scientists studying cannabis medicine agree that if the dose could be increased ten or a hundred times, its already substantial efficacy will be greatly increased. Now this is possible thanks to the removal of the 'high' from the cannabinoids in the production of Dharmanol™."

"The low-dose, non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in 'stimulating' a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should."





(0)
(0)




SK3 Group Inc. (SKTO) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us